Warfarin Resistance: A Case Report
Warfarin is the most widely prescribed anticoagulant in the world. Patients who need more than 15 mg per day should be considered warfarin-resistant. Nearly 30 genes have been reported in association with warfarin pharmacogenetics but genetic polymorphisms in the genes encoding CYP2C9 and VKORC1 hav...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2019-03-01
|
| Series: | Eurasian Journal of Emergency Medicine |
| Subjects: | |
| Online Access: |
http://akademikaciltip.com/archives/archive-detail/article-preview/warfarin-resistance-a-case-report/24295
|
| _version_ | 1797915254616752128 |
|---|---|
| author | Uğur Gönlügür Tanseli Gönlügür Öztürk Özdemir Fatma Sılan |
| author_facet | Uğur Gönlügür Tanseli Gönlügür Öztürk Özdemir Fatma Sılan |
| author_sort | Uğur Gönlügür |
| collection | DOAJ |
| description | Warfarin is the most widely prescribed anticoagulant in the world. Patients who need more than 15 mg per day should be considered warfarin-resistant. Nearly 30 genes have been reported in association with warfarin pharmacogenetics but genetic polymorphisms in the genes encoding CYP2C9 and VKORC1 have been shown to act as the most important determinants of drug dosage requirements. The major enzyme responsible for the metabolism of S-warfarin, the more potent of warfarin’s two stereoisomers, is CYP2C9. Warfarin inhibits vitamin K epoxide reductase (VKOR). A 30-year-old woman was referred to our clinic for pulmonary embolism. She was treated with low molecular weight heparin. The warfarin dose was titrated up to 15 mg daily but after one week, the INR (international normalized ratio) was still subtherapeutic level at 1.8. In this paper, we discuss underlying genetic polymorphisms about warfarin resistance. |
| first_indexed | 2024-04-10T12:39:58Z |
| format | Article |
| id | doaj.art-bab82961829d425895ff64746b2c0022 |
| institution | Directory Open Access Journal |
| issn | 2149-5807 2149-6048 |
| language | English |
| last_indexed | 2024-04-10T12:39:58Z |
| publishDate | 2019-03-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | Eurasian Journal of Emergency Medicine |
| spelling | doaj.art-bab82961829d425895ff64746b2c00222023-02-15T16:14:24ZengGalenos YayineviEurasian Journal of Emergency Medicine2149-58072149-60482019-03-01181616310.4274/eajem.galenos.2018.4103313049054Warfarin Resistance: A Case ReportUğur Gönlügür0Tanseli Gönlügür1Öztürk Özdemir2Fatma Sılan3 Department of Chest Diseases, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Turkey Clinic of Chest Diseases, Çanakkale City Hospital, Çanakkale, Turkey Department of Medical Genetics, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Turkey Department of Medical Genetics, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Turkey Warfarin is the most widely prescribed anticoagulant in the world. Patients who need more than 15 mg per day should be considered warfarin-resistant. Nearly 30 genes have been reported in association with warfarin pharmacogenetics but genetic polymorphisms in the genes encoding CYP2C9 and VKORC1 have been shown to act as the most important determinants of drug dosage requirements. The major enzyme responsible for the metabolism of S-warfarin, the more potent of warfarin’s two stereoisomers, is CYP2C9. Warfarin inhibits vitamin K epoxide reductase (VKOR). A 30-year-old woman was referred to our clinic for pulmonary embolism. She was treated with low molecular weight heparin. The warfarin dose was titrated up to 15 mg daily but after one week, the INR (international normalized ratio) was still subtherapeutic level at 1.8. In this paper, we discuss underlying genetic polymorphisms about warfarin resistance. http://akademikaciltip.com/archives/archive-detail/article-preview/warfarin-resistance-a-case-report/24295 Warfarinvitamin K epoxide reductasesVKORC1 |
| spellingShingle | Uğur Gönlügür Tanseli Gönlügür Öztürk Özdemir Fatma Sılan Warfarin Resistance: A Case Report Eurasian Journal of Emergency Medicine Warfarin vitamin K epoxide reductases VKORC1 |
| title | Warfarin Resistance: A Case Report |
| title_full | Warfarin Resistance: A Case Report |
| title_fullStr | Warfarin Resistance: A Case Report |
| title_full_unstemmed | Warfarin Resistance: A Case Report |
| title_short | Warfarin Resistance: A Case Report |
| title_sort | warfarin resistance a case report |
| topic | Warfarin vitamin K epoxide reductases VKORC1 |
| url |
http://akademikaciltip.com/archives/archive-detail/article-preview/warfarin-resistance-a-case-report/24295
|
| work_keys_str_mv | AT ugurgonlugur warfarinresistanceacasereport AT tanseligonlugur warfarinresistanceacasereport AT ozturkozdemir warfarinresistanceacasereport AT fatmasılan warfarinresistanceacasereport |